Natural origin stabilizer for oil in water emulsions
The present invention relates to the use of a methacrylate or acrylate modified polysaccharide; or a single-chain polysaccharide methacrylate or acrylate-based nanoparticle, having a surface tension measured by Du Noüy Ring method equal to or lower than 63 mN/m, as oil-in-water emulsion stabilizer; and an oil-in-water emulsion stabilizer composition, and an oil-in-water emulsion containing them. It also relates to processes for their preparation, and their uses.
1. An oil-in-water emulsion comprising:
(a) an external water phase (W) comprising:
(a1) a solvent selected from the group consisting of water, glycol, and a mixture thereof; and
(a2) optionally, one or more hydrophilic compounds selected from the group consisting of: (a2′) hydrophilic active agent and (a2″) hydrophilic excipients or carriers;
(b) the internal oily phase (O) comprising one or more lipophilic compounds selected from the group consisting of:
(b1) lipophilic active agents, and
(b2) lipophilic excipients or carriers;
and
(c) an interfacial layer (IL) between the external water phase (W) and the internal oily phase (O) comprising:
(c1) one or more emulsion stabilizer selected from the group consisting of:
(c1′) methacrylate or acrylate modified polysaccharides having a surface tension measured by Du Noüy Ring method equal to or lower than 63 mN/m;
(c1″) single-chain polysaccharide methacrylate or acrylate-based nanoparticles having a surface tension measured by Du Noüy Ring method equal to or lower than 63 mN/m;
(c1′″) interfacial crosslinked methacrylate or acrylate modified polysaccharides obtainable by reacting the methacrylate or acrylate modified polysaccharides as defined in (c1′) with an interfacial crosslinking agent, wherein the interfacial crosslinked methacrylate or acrylate modified polysaccharides has an interfacial crosslinking degree from 25 to 100% of the methacrylate or acrylate groups of the polysaccharide; or alternatively,
(c1″″) interfacial crosslinked single-chain polysaccharide methacrylate or acrylate based nanoparticles obtainable by reacting the single-chain polysaccharide methacrylate or acrylate-based nanoparticles as defined in (c1″) with an interfacial crosslinking agent, wherein the interfacial crosslinked single-chain polysaccharide methacrylate or acrylate based nanoparticles has an interfacial crosslinking degree from 25 to 100% of the methacrylate or acrylate groups of the nanoparticles;
wherein the carbon atom of the group —CO— of the methacrylate or acrylate moiety is covalently bonded to the oxygen atom of the OH— moiety of the polysaccharide; and
c2) optionally, one or more hydrophilic active agents.
2. The oil-in-water emulsion according to claim 1 , wherein the active agent is selected from the group consisting of a pharmaceutical active ingredient, a diagnostic agent and a cosmetic agent.
3. The oil-in-water emulsion according to claim 1 , wherein the emulsion is absent of active agents, as a carrier.
4. A method of therapy, the method comprising:
using an oil-in-water emulsion according to claim 1 , wherein the emulsion is a pharmaceutical emulsion comprising one or more pharmaceutical active ingredients as the active agent.
5. The method according to claim 4 , wherein the emulsion is a pharmaceutical emulsion comprising one or more pharmaceutical active ingredients as the active agent selected from the group consisting of: vasoactive agents; neuroactive agents; hormones; growth factors; cytokines; anaesthetics; steroids; anticoagulants, D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, a polylysine-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and ticlc antiplatelet peptides; anti-inflammatories, steroids, dexamethasone, prednisolone, triamcinolone, fluorometholone, betamethasone, budesonide, hydrocortisone, clobetasone, beclometasone, desoximetasone, methylprednisolone, non-steroid agents (AINE), dicoflenac, aceclofenac, benzydamine, dexketoprofen, etofenamate, fepradinol, ibuprofen, indomethacin, ketoprofen, and piroxicam; immunomodulating agents; cytotoxic agents; prophylactic agents; antivirals; antigens; antibodies; anti-thrombogenic agents, heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents, enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); antineoplastic/antiproliferative/anti-miotic agents, paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, and thymidine kinase inhibitors; anaesthetic agents, lidocaine, bupivacaine, and ropivacaine; vascular cell growth promoters, growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms; radiopharmaceutical; analgesic drugs; anorectic agents; anti-anaemia agents; anti-asthma agents; anti-diabetic agents; antihistamine, diphenydramine, dimetindene, and promethazine; antimuscarinic drugs; cardiovascular drugs; central nervous system stimulator; central nervous system depressant; anti-depressant; anti-epileptic; anxiolytic agents; hypnotic agents; sedative; beta blocker; homeostatic agents; hormone; vasodilator; vasoconstrictor; vitamin; chemotherapeutics including antivirals, acyclovir, penciclovir, valaciclovir, idoxuridine, tromantadine, imiquimod, and metronidazole; antibiotics, fusidic acid, mupirocin, gentamicin, neomycin, retapamulin, clindamycin, erithromycin, and chlortetracycline; antifungals, imidazole and triazole derivatives, bifonazole, chlotrimazole, eberconazole, econazole, fenticonazole, flutrimazole, ketoconazole, miconazole, oxiconazole, sertaconazole, thioconazole; nistatin, Naftifine, terbinafine, tolnaftate, and ciclopirox; healing agents, Arnica montana, Centella asiatica , and becaplermin; local anesthetics, lidocaine, benzocaine, and tetracaine; anti-psoriatic agents, etanercept, adalimumab, ustekinumab, dithranol, calcipotriol, calcitriol, tacalcitol, and tazarotene; retinoid agents, tretinoin, isotretinoin, and adapalene; antiseptic and desinfectant agents, chlorhexidine, boric acid, and triclosan; tacrolimus; hydroquinone; minoxidil; Finasteride; Gastro-intestinal; Antitussive agents; Expectorants; anti-spasmodics; diuretics; antihemorrhoidals; hypnotics, psychotropic; decongestants; laxant; and antiacid.
6. The oil-in-water emulsion according to claim 1 , wherein the emulsion is a cosmetic emulsion comprising one or more cosmetic agent, as a skin or hair care agent.
7. The oil-in-water emulsion according to claim 1 , wherein the emulsion is a diagnostic emulsion comprising one or more diagnostic agent, for use in diagnosis.
8. The oil-in-water emulsion according to claim 7 , wherein the diagnostic agent is a diagnostically imaging acceptable agent selected from the group consisting of fluorescent agent, contrast agent, and radioimaging agent.
9. The oil-in-water emulsion according to claim 1 , wherein the diagnostic agent is a diagnostically imaging acceptable selected from the group consisting of diethylene triamine pentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), fluorescein, rhodamine, and cyane 5,5.
10. The oil in water emulsion according to claim 1 , wherein the methacrylate or acrylate modified polysaccharide has a surface tension measured by Du Noüy Ring method equal to or lower than 60 mN/m.
11. The oil in water emulsion according to claim 1 , wherein the polysaccharide is selected from dextran, hyaluronic acid, alginate, gellan gum, cellulose and a derivative thereof, glycogen, and chitosan.
12. The oil in water emulsion according to claim 1 , wherein the polysaccharide is selected from dextran, hyaluronic acid, and chitosan.
13. The oil in water emulsion according to claim 1 , wherein the degree of substitution of the polysaccharide with the methacrylate or acrylate groups is from 1 to 100% of modified repeating units of the polysaccharide.
14. The oil in water emulsion according to claim 1 , the degree of substitution of the nanoparticles with methacrylate or acrylate groups is from 1% to 98% of modified repeating units of the nanoparticles.
15. The oil in water emulsion according to claim 1 ), wherein the methacrylate or acrylate modified polysaccharide is selected from the group consisting of a methacrylate modified dextran having a degree of substitution of the methacrylate groups from 1% to 100% of modified repeating units of the dextran and comprising repeating units of formula (I):
and an acrylate modified dextran having a degree of substitution of the acrylate groups from 1% to 100% of modified repeating units of the dextran and comprising repeating units of formula (II):
16. The oil in water emulsion according to claim 1 , wherein the single-chain polysaccharide methacrylate or acrylate-based nanoparticle is a single-chain dextran methacrylate or acrylate-based nanoparticle having:
a degree of substitution of the dextran with methacrylate or acrylate groups from 1% to 98% of modified repeating units of the nanoparticles; and
a percentage of intra-molecular crosslinking from 1 to 60 molar % of the total amount of monomer units present in the dextran methacrylate or acrylate chain.
17. The oil in water emulsion according to claim 1 , wherein the methacrylate or acrylate modified polysaccharide is selected from the group consisting of a methacrylate modified hyaluronic acid having a degree of substitution of the methacrylate groups from 1% to 100% of modified repeating units of the hyaluronic acid and comprising repeating units of formula (IV):
and an acrylate modified hyaluronic acid having a degree of substitution of the acrylate groups from 1% to 100% of modified repeating units of the hyaluronic acid and comprising repeating units of formula (V):
or alternatively, wherein the single-chain polysaccharide methacrylate or acrylate-based nanoparticle is a single-chain hyaluronic acid methacrylate or acrylate-based nanoparticle having:
a degree of substitution of the hyaluronic acid with methacrylate or acrylate groups from 1% to 98% of modified repeating units of the nanoparticles; and
a percentage of intra-molecular crosslinking from 1 to 60 molar % of the total amount of monomer units present in the hyaluronic acid methacrylate or acrylate chain.
18. The oil in water emulsion according to claim 1 , wherein the methacrylate or acrylate modified polysaccharide is selected from the group consisting of a methacrylate modified chitosan having a degree of substitution of the methacrylate groups from 1% to 100% of the repeating units of chitosan and comprising repeating units of formula (VII):
and an acrylate modified chitosan having a degree of substitution of the chitosan with acrylate groups from 1% to 100% of the repeating units of chitosan and comprising repeating units of formula (VIII):
or alternatively, wherein the single-chain polysaccharide methacrylate or acrylate-based nanoparticle is a single-chain chitosan methacrylate or acrylate-based nanoparticle having:
a degree of substitution of the chitosan with methacrylate or acrylate groups from 1% to 98% of modified repeating units of the nanoparticles; and
a percentage of intra-molecular crosslinking from 1 to 60 molar % of the total amount of monomer units present in the chitosan methacrylate or acrylate chain.